Last week the Senate Judiciary Committee shelved a proposed bill aimed at curbing patent abuse, but according to some experts, the setback does not mean patent trolls should not be concerned about patent reform.
According to reports, Congress is set to pick up its task of patent reform after the recess as advocates call for legislation to curb the practice of patent assertion entities excessively suing companies that use those patents or demanding unfair royalty fees.
The Federal Trade Commission announced earlier this month it would be requesting information from 25 patent assertion entities about their practices. Further, reports say, recent court cases have strengthened and clarified patent-related law; a late-April ruling encouraged judges to impose an order for winning parties to be awarded attorneys fees in patent litigation.
An impending Supreme Court case, set to be decided by the end of next month, could offer new methods against patent trolls as well. SCOTUS is slated to offer its opinions of two cases, one regarding patent infringement and the other regarding patent claims.
As reports suggest, several other instances show that the Congressional recess in August is unlikely to take patent reform off the minds of lawmakers.
Full content: Forbes
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas